Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.

导出原文传递

翻译打印收藏纠错

第一作者： Ariadna,Tibau

第一单位： Hospital Santa Crau y Sant Pau, Barcelona, Spain.

作者： Ariadna,Tibau ^[1] ; Laura,Díez-González ^[2] ; Beatriz,Navarro ^[3] ; Eva M,Galán-Moya ^[2] ; Arnoud J,Templeton ^[4] ; Bostjan,Seruga ^[5] ; Atanasio,Pandiella ^[6] ; Eitan,Amir ^[7] ; Alberto,Ocana ^[8]

作者单位： Hospital Santa Crau y Sant Pau, Barcelona, Spain. ^[1] Translational Research Unit, CIBERONC, Albacete University Hospital, Albacete, Spain. ^[2] Clinical Research Support Unit, Albacete University Hospital, Albacete and Fundación Hospital Nacional de Paraplejicos, Toledo, Spain. ^[3] Department of Medical Oncology and Hematology, St. Claraspital, Basel, Switzerland. ^[4] Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. ^[5] IBMCC-CSIC, Universidad de Salamanca, Salamanca, Spain. ^[6] Divisions of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. ^[7] Translational Research Unit, CIBERONC, Albacete University Hospital, Albacete, Spain. albertoo@sescam.jccm.es. ^[8] Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Edificio de Investigación, Calle Francisco Javier de Moya, 02006, Albacete, Spain. albertoo@sescam.jccm.es. ^[9] Regional Biomedical Research Center (CRIB), Castilla La Mancha University, Albacete, Spain. albertoo@sescam.jccm.es. ^[10]